清滋飲對陰虛血瘀證2型糖尿病患者視黃醇結(jié)合蛋白、胱抑素C影響的觀察
發(fā)布時間：2018-09-07 10:48
【摘要】：目的:觀察清滋飲對2型糖尿病陰虛血瘀證患者的RBP、CysC的影響及臨床療效與安全性。方法:本研究在隨機(jī)對照原則指導(dǎo)下,將符合此次研究標(biāo)準(zhǔn)的60例患者,隨機(jī)分為試驗(yàn)組和對照組。其中前者在西醫(yī)常規(guī)基礎(chǔ)治療之上加上清滋飲內(nèi)服,后者僅用西醫(yī)常規(guī)基礎(chǔ)治療,兩組的治療療程相同,均為12周。通過對兩組治療前后血清視黃醇結(jié)合蛋白(RBP)、胱抑素 C(CysC)及其他實(shí)驗(yàn)室指標(biāo)(如 BMI、HbAlc、FBG、PBG、TC、TG、LDL-C、HDL-C、Lp(a)、Apo-A、Apo-B、Scr、eGFR等)的變化進(jìn)行比較,觀察其對血清視黃醇結(jié)合蛋白、CysC的影響及臨床療效與安全性。結(jié)果:治療后,兩組臨床癥狀總評分及血糖等相關(guān)實(shí)驗(yàn)室指標(biāo)較未治療前均有改善(P0.05),且試驗(yàn)組優(yōu)于對照組。試驗(yàn)組臨床癥狀改善總體有效率為93%,對照組為73%。治療后兩組血脂譜較治療前均有優(yōu)化(P0.05),在改善TC、TG、LDL-C方面,試驗(yàn)組優(yōu)于對照組。治療后兩組Apo-B較治療前均有下降(P0.05),且試驗(yàn)組下降幅度優(yōu)于對照組。治療后CysC、RBP試驗(yàn)組較治療前均有下降(P0.05),對照組較治療前無明顯統(tǒng)計學(xué)差異(P0.05)。治療后Scr、eGFR試驗(yàn)組較治療前均有改善(P0.05),對照組較治療前無明顯統(tǒng)計學(xué)差異(P0.05)。治療前后兩組肝腎功能比較無明顯差異,兩組治療前后均無明顯不良反應(yīng)。結(jié)論:清滋飲治療陰虛血瘀證2型糖尿病患者療效確切,能降低其證候積分、血糖,調(diào)節(jié)血脂,降低Apo-B,可降低血清CysC、RBP,改善Scr、eGFR,且無明顯不良反應(yīng),安全可靠。
[Abstract]:Objective: to observe the effect of Qingzi decoction on RBP,CysC and its clinical efficacy and safety in type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. Methods: under the guidance of randomized control principle, 60 patients who met the criteria of this study were randomly divided into trial group and control group. The former plus Qingzi Yin on the basis of routine western medicine treatment, the latter was only treated with routine western medicine, the two groups were treated for the same course of treatment, both for 12 weeks. By comparing the changes of serum retinol binding protein (RBP), cystatin C (CysC), and other laboratory indexes (such as BMI,HbAlc,FBG,PBG,TC,TG,LDL-C,HDL-C,Lp (a) Apo-An Apo-Bnus ScreGFR, etc.) before and after treatment, the effects, clinical efficacy and safety of serum retinol binding protein (retinol binding protein), CysC, were observed. Results: after treatment, the clinical symptom score and blood sugar were improved in both groups (P0.05), and the experimental group was superior to the control group. The overall effective rate of clinical symptom improvement was 93 in the trial group and 73 in the control group. The blood lipid spectrum of the two groups was optimized after treatment (P0.05), and the experimental group was superior to the control group in improving TC,TG,LDL-C. After treatment, the Apo-B of the two groups was lower than that of the control group (P0.05), and the decrease of Apo-B in the experimental group was better than that in the control group. After treatment, the CysC,RBP test group were lower than before treatment (P0.05), the control group had no statistical difference compared with before treatment (P0.05). After treatment, Scr,eGFR test group were improved compared with before treatment (P0.05), the control group had no significant difference compared with before treatment (P0.05). There was no significant difference in liver and kidney function between the two groups before and after treatment. Conclusion: Qingzi decoction is effective in treating type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. It can reduce syndromes score, blood sugar, regulate blood lipid, and reduce serum CysC,RBP, to improve Scr,eGFR,. There is no obvious adverse reaction and it is safe and reliable.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R259
本文編號：2228047
[Abstract]:Objective: to observe the effect of Qingzi decoction on RBP,CysC and its clinical efficacy and safety in type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. Methods: under the guidance of randomized control principle, 60 patients who met the criteria of this study were randomly divided into trial group and control group. The former plus Qingzi Yin on the basis of routine western medicine treatment, the latter was only treated with routine western medicine, the two groups were treated for the same course of treatment, both for 12 weeks. By comparing the changes of serum retinol binding protein (RBP), cystatin C (CysC), and other laboratory indexes (such as BMI,HbAlc,FBG,PBG,TC,TG,LDL-C,HDL-C,Lp (a) Apo-An Apo-Bnus ScreGFR, etc.) before and after treatment, the effects, clinical efficacy and safety of serum retinol binding protein (retinol binding protein), CysC, were observed. Results: after treatment, the clinical symptom score and blood sugar were improved in both groups (P0.05), and the experimental group was superior to the control group. The overall effective rate of clinical symptom improvement was 93 in the trial group and 73 in the control group. The blood lipid spectrum of the two groups was optimized after treatment (P0.05), and the experimental group was superior to the control group in improving TC,TG,LDL-C. After treatment, the Apo-B of the two groups was lower than that of the control group (P0.05), and the decrease of Apo-B in the experimental group was better than that in the control group. After treatment, the CysC,RBP test group were lower than before treatment (P0.05), the control group had no statistical difference compared with before treatment (P0.05). After treatment, Scr,eGFR test group were improved compared with before treatment (P0.05), the control group had no significant difference compared with before treatment (P0.05). There was no significant difference in liver and kidney function between the two groups before and after treatment. Conclusion: Qingzi decoction is effective in treating type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. It can reduce syndromes score, blood sugar, regulate blood lipid, and reduce serum CysC,RBP, to improve Scr,eGFR,. There is no obvious adverse reaction and it is safe and reliable.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R259
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 張懷民;傅秀慧;鄭海洲;;中藥活性成分治療2型糖尿病及其并發(fā)癥作用機(jī)制的研究進(jìn)展[J];中國藥房;2016年22期
2 王小官;曾勇;;玉液止渴丸治療消渴病(氣陰兩虛證)的臨床研究[J];湖北中醫(yī)雜志;2015年12期
3 高靜;段暢;李麗娟;;2型糖尿病發(fā)病機(jī)制的研究進(jìn)展[J];醫(yī)學(xué)綜述;2015年21期
4 付廣真;張曼;;2型糖尿病伴背景性及增殖性視網(wǎng)膜病變的血脂六項(xiàng)分析[J];中國衛(wèi)生檢驗(yàn)雜志;2015年07期
5 晏斌;王洪彬;喇孝瑾;李繼安;;中藥防治2型糖尿病的臨床用藥分析[J];中國民族民間醫(yī)藥;2014年13期
6 周慎;戴芳芳;;連蘇飲加減治療糖尿病胃輕癱醫(yī)案三則[J];實(shí)用中醫(yī)內(nèi)科雜志;2014年02期
7 張高健;邱蔚;;2型糖尿病合并冠心病患者血清內(nèi)脂素和視黃醇結(jié)合蛋白4的臨床意義[J];心腦血管病防治;2013年03期
8 龐博;趙進(jìn)喜;王世東;祝勇;李景;;祝諶予診療糖尿病學(xué)術(shù)思想與臨證經(jīng)驗(yàn)[J];世界中醫(yī)藥;2013年02期
9 王艷梅;徐遠(yuǎn);;徐遠(yuǎn)教授“達(dá)肝法”在消渴病治療中的應(yīng)用[J];世界中西醫(yī)結(jié)合雜志;2012年08期
10 崔鵬;李繼安;;中藥有效成分改善2型糖尿病胰島素抵抗的研究進(jìn)展[J];中國煤炭工業(yè)醫(yī)學(xué)雜志;2012年05期
，本文編號：2228047
本文鏈接：http://sikaile.net/zhongyixuelunwen/2228047.html
最近更新
教材專著
